Citizens Reiterates Market Outperform on Abivax, Maintains $187 Price Target
Citizens analyst Jason N. Butler reiterates Abivax (NASDAQ: ABVX ) with a Market Outperform and maintains $187 price target.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.